研飞客户端支持数万种期刊查询，助你在阅读和写作中随时了解期刊动态
Nucleic Acid Therapeutics
| 短名 | Nucleic Acid Ther. |
| Journal Impact | 4.09 |
| 国际分区 | MEDICINE, RESEARCH & EXPERIMENTAL(Q2) |
| 期刊索引 | SCI Q2中科院 2 区 |
| ISSN | 2159-3337, 2159-3345 |
| h-index | 77 |
| 国内分区 | 医学(2区)医学生化与分子生物学(2区)医学药物化学(2区)医学医学研究与实验(3区) |
《Nucleic Acid Therapeutics》是该领域的领先期刊，专注于利用核酸及相关化合物改变基因表达的前沿基础研究、治疗应用和药物开发。该杂志探讨了多种使用核酸作为治疗剂或修饰核酸以实现治疗目的的新方法，包括寡核苷酸、基因修饰、适体、RNA纳米颗粒和核酶。
期刊主页投稿网址阅读文献时，研飞即可帮你快速了解期刊，查询影响因子与分区，智能高亮期刊预警！
| 涉及主题 | 生物遗传学化学生物化学基因医学内科学核糖核酸DNA分子生物学细胞生物学寡核苷酸细胞培养计算生物学物理有机化学免疫学转染药理学 |
| 出版信息 | 出版商: Mary Ann Liebert Inc.，出版周期: ，期刊类型: journal |
| 基本数据 | 创刊年份: 2011，原创研究文献占比: 97.56%，自引率:5.00%， Gold OA占比: 43.69% |
| 平均审稿周期 | 网友分享经验：>12周，或约稿 |
| 平均录用比例 | 网友分享经验：容易 |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
手工熬夜修改参考文献？研飞自动匹配期刊，一键轻松成稿，支持 Word/WPS
点击下方按钮，免费开启试用！
最新文章
Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells
2024-9-12
Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy
2024-8-27
Mass Spectrometry as a Quantitative Tool for SpCas9 sgRNA Quality Control
2024-8-23
A Guide to Chemical Considerations for the Pre-Clinical Development of Oligonucleotides
2024-8-7
Levels of Exon-Skipping Are Not Artificially Overestimated Because of the Increased Affinity of Tricyclo-DNA-Modified Antisense Oligonucleotides to the Target <i>DMD</i> Exon
2024-7-24
Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity
2024-7-22
mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs <i>In Vivo</i>
2024-7-18
Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides
2024-7-17
Preclinical Pharmacokinetics in Tumors and Normal Tissues of the Antigene PNA Oligonucleotide MYCN-Inhibitor BGA002
2024-7-3
Phosphorothioates and Me: A Lecture About My 35 Years in Oligo-World on My Receipt of the 2023 Lifetime Achievement Award of the Oligonucleotide Therapeutics Society
2024-6-26
Antisense Oligonucleotide-Based Rescue of Complex Intronic Splicing Defects in <i>ABCA4</i>
2024-5-27
Multiplexed <i>In Vivo</i> Screening Using Barcoded Aptamer Technology to Identify Oligonucleotide-Based Targeting Reagents
2024-5-16
Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids
2024-5-8
Sequence- and Structure-Dependent Cytotoxicity of Phosphorothioate and 2′-<i>O</i>-Methyl Modified Single-Stranded Oligonucleotides
2024-4-22
Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment
2024-4-19
<i>Correction to:</i> Understanding and Rescuing the Splicing Defect Caused by the Frequent <i>ABCA4</i> Variant c.4253 + 43G>A Underlying Stargardt Disease, by Nuria Suárez-Herrera et al., Nucleic Acid Ther 2024;34(2):73–82; doi: 10.1089/nat.2023.0076
2024-4-17
Splice-Switching Antisense Oligonucleotides Correct Phenylalanine Hydroxylase Exon 11 Skipping Defects and Rescue Enzyme Activity in Phenylketonuria
2024-4-9
Considerations for Creating the Next Generation of RNA Therapeutics: Oligonucleotide Chemistry and Innate Immune Responses to Nucleic Acids
2024-4-1
Extracellular Vesicles Loaded with Long Antisense RNAs Repress Severe Acute Respiratory Syndrome Coronavirus 2 Infection
2024-3-26
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
2024-3-20
Understanding and Rescuing the Splicing Defect Caused by the Frequent <i>ABCA4</i> Variant c.4253+43G>A Underlying Stargardt Disease
2024-3-11
Simplified Oligonucleotide Phosphorus Deprotection Process with Reduced 3-(2-Cyanoethyl) Thymidine Impurities
2024-2-5
Biodistribution of Radioactively Labeled Splice Modulating Antisense Oligonucleotides After Intracerebroventricular and Intrathecal Injection in Mice
2024-2-1
“Goldilocks Modifications” for mRNA Therapeutics Won the Nobel Prize
2024-1-29
Reversible Aptamer Staining, Sorting, and Cleaning of Cells (Clean FACS) with Antidote Oligonucleotide or Nuclease Yields Fully Responsive Cells
2024-1-29
Safety and Tolerability of GalNAc<sub>3</sub>-Conjugated Antisense Drugs Compared to the Same-Sequence 2′-<i>O</i>-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data
2024-1-16
RNA Interference Effectors Selectively Silence the Pathogenic Variant <i>GNAO1</i> c.607 G > A <i>In Vitro</i>
2024-1-12
Report of the European Medicines Agency Conference on RNA-Based Medicines
2024-1-4
Acknowledgment of Reviewers 2023
2023-12-14
Challenges of Assessing Exon 53 Skipping of the Human <i>DMD</i> Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy
2023-11-27
Impact of the Inhibition of Organic Anion Transporter on Tricyclo-DNA-Mediated Exon Skipping in the <i>mdx</i> Mouse Model
2023-11-15
Cholesterol-Conjugated Supramolecular Multimeric siRNAs: Effect of siRNA Length on Accumulation and Silencing <i>In Vitro</i> and <i>In Vivo</i>
2023-11-9
Modulation of Gene Expression in the Eye with Antisense Oligonucleotides
2023-11-2
Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome
2023-10-2
Development of Long Asymmetric siRNA Structure for Target Gene Silencing and Immune Stimulation in Mammalian Cells
2023-10-1
Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients
2023-8-29
New Oligonucleotide 2′-O-Alkyl N3′→P5′ (Thio)-Phosphoramidates as Potent Antisense Agents: Physicochemical Properties and Biological Activity
2023-8-28
OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides
2023-8-17
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for <i>Nucleic Acid Therapeutics</i>
2023-8-1
From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of <i>SOD1</i> Mutated Amyotrophic Lateral Sclerosis
2023-8-1
mTOR Inhibition Enhances Delivery and Activity of Antisense Oligonucleotides in Uveal Melanoma Cells
2023-6-30
Sequence-Controlled Spherical Nucleic Acids: Gene Silencing, Encapsulation, and Cellular Uptake
2023-5-17
Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics
2023-5-5
DNAzymes: Expanding the Potential of Nucleic Acid Therapeutics
2023-4-24
Complement C3d/C4d Deposition on Platelets Correlates with 2′-O-Methoxyethyl Antisense Oligonucleotide-Induced Thrombocytopenia in Monkeys
2023-4-24
Positive Allosteric Modulation of Antithrombin's Inhibitory Activity by RNA Aptamers
2023-4-24
Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
2023-4-10
Rapid and Reliable Quantification of Prime Editing Targeting Within the Porcine <i>ABCA4</i> Gene Using a BRET-Based Sensor
2023-3-1
Aerosolized Pulmonary Delivery of mRNA Constructs Attenuates Severity of <i>Escherichia coli</i> Pneumonia in the Rat
2023-2-22
Considerations for the Terminal Sterilization of Oligonucleotide Drug Products
2023-2-14
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远